Similar articles for PMID: 32988912

Year	Number of Results
1997	1
1998	1
2000	1
2002	2
2003	2
2005	2
2006	1
2007	1
2008	5
2010	3
2011	6
2012	5
2013	4
2014	8
2015	10
2016	14
2017	16
2018	8
2019	10
2020	14
2021	5
2022	7
2023	4
2024	0

1

Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer.

Tanishima Y, Nishikawa K, Arakawa Y, Matsumoto A, Yuda M, Tanaka Y, Mitsumori N, Yanaga K. Tanishima Y, et al. Anticancer Res. 2020 Oct;40(10):5829-5835. doi: 10.21873/anticanres.14601. Anticancer Res. 2020. PMID: 32988912

2

Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.

Yamagata Y, Saito K, Hirano K, Oya M. Yamagata Y, et al. World J Surg Oncol. 2020 Sep 22;18(1):252. doi: 10.1186/s12957-020-02023-2. World J Surg Oncol. 2020. PMID: 32962718 Free PMC article.

3

Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.

Sugimura K, Miyata H, Shinno N, Ushigome H, Asukai K, Yanagimoto Y, Hasegawa S, Takahashi Y, Yamada D, Yamamoto K, Nishimura J, Motoori M, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Yano M. Sugimura K, et al. Oncology. 2019;97(6):348-355. doi: 10.1159/000502342. Epub 2019 Aug 28. Oncology. 2019. PMID: 31461716

4

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.

Yamashita K, Hosoda K, Moriya H, Katada C, Sugawara M, Mieno H, Komori S, Katada N, Watanabe M. Yamashita K, et al. Oncology. 2017;92(4):221-228. doi: 10.1159/000455128. Epub 2017 Jan 21. Oncology. 2017. PMID: 28110330

5

Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.

Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, Iwagami S, Baba H. Watanabe M, et al. Ann Surg Oncol. 2014 Sep;21(9):2838-44. doi: 10.1245/s10434-014-3684-8. Epub 2014 Apr 9. Ann Surg Oncol. 2014. PMID: 24715216

6

Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.

Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, Martin JM, Burge M, Finch R, Karapetis CS, Shannon J, Nott LM, Varma S, Marx G, Falk GL, Gebski V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcberg JR, Simes J, Smithers BM; DOCTOR investigators. Barbour AP, et al. Ann Oncol. 2020 Feb;31(2):236-245. doi: 10.1016/j.annonc.2019.10.019. Epub 2019 Dec 23. Ann Oncol. 2020. PMID: 31959340 Free article. Clinical Trial.

7

Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.

Akiyama Y, Iwaya T, Endo F, Chiba T, Takahara T, Otsuka K, Nitta H, Koeda K, Mizuno M, Kimura Y, Sasaki A. Akiyama Y, et al. Surg Endosc. 2018 Jan;32(1):391-399. doi: 10.1007/s00464-017-5688-5. Epub 2017 Jun 29. Surg Endosc. 2018. PMID: 28664431

8

Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.

Sasaki K, Uchikado Y, Omoto I, Arigami T, Osako Y, Noda M, Okumura H, Maemura K, Higashi R, Yoshiura T, Natsugoe S. Sasaki K, et al. Cancer Chemother Pharmacol. 2019 Mar;83(3):581-587. doi: 10.1007/s00280-018-03764-4. Epub 2019 Jan 8. Cancer Chemother Pharmacol. 2019. PMID: 30623230

9

Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications.

Hirao M, Ando N, Tsujinaka T, Udagawa H, Yano M, Yamana H, Nagai K, Mizusawa J, Nakamura K; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Hirao M, et al. Br J Surg. 2011 Dec;98(12):1735-41. doi: 10.1002/bjs.7683. Epub 2011 Sep 14. Br J Surg. 2011. PMID: 21918956 Clinical Trial.

10

Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.

Sugase T, Sugimura K, Kanemura T, Takeoka T, Yamamoto M, Shinno N, Hara H, Omori T, Fujii Y, Mukai Y, Mikamori M, Hasegawa S, Haraguchi N, Akita H, Nishimura J, Wada H, Matsuda C, Yasui M, Miyata H. Sugase T, et al. Oncology. 2022;100(12):655-665. doi: 10.1159/000527196. Epub 2022 Oct 5. Oncology. 2022. PMID: 36198297

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

109 results

Results by year